A "Chemical ChatGPT" for New Medications

Researchers from the University of Bonn have trained an AI process to predict potential active ingredients with special properties. Therefore, they derived a chemical language model - a kind of ChatGPT for molecules. Following a training phase, the AI was able to exactly reproduce the chemical structures of compounds with known dual-target activity that may be particularly effective medications. The study has now been published in Cell Reports Physical Science.

Anyone who wants to delight their granny with a poem on her 90th birthday doesn’t need to be a poet nowadays: A short prompt in ChatGPT is all it takes, and within a few seconds the AI spits out a long list of words that rhyme with the birthday girl’s name. It can even produce a sonnet to go with it if you like.

Researchers at the University of Bonn have implemented a similar model in their study – known as a chemical language model. This does not, however, produce rhymes. Instead, the AI displays the structural formulas of chemical compounds that may have a particularly desirable property: They are able to bind to two different target proteins. In the organism, this means, for example, they can inhibit two enzymes at once.

"2In pharmaceutical research, these types of active compounds are highly desirable due to their polypharmacology," explains Prof. Dr. Jürgen Bajorath. The computational chemistry expert heads the AI in Life Sciences area at the Lamarr Institute for Machine Learning and Artificial Intelligence and the Life Science Informatics program at b-it (Bonn-Aachen International Center for Information Technology) at Uni Bonn. "Because compounds with desirable multi-target activity influence several intracellular processes and signaling pathways at the same time, they are often particularly effective - such as in the fight against cancer." In principle, this effect can also be achieved by co-administration of different drugs. However, there is a risk of unwanted drug-drug interactions and different compounds are also often broken down at different rates in the body, making it difficult to administer them together.

Finding a molecule that specifically influences the effect of a single target protein is no easy task. Designing compounds that have a predefined double effect is even more complicated. Chemical language models may help here in the future. ChatGPT is trained with billions of pages of written text and learns to formulate sentences itself. Chemical language models work in a similar way, but only have comparably very small amounts of data available for learning. However, in principle, they are also fed with texts, such as what are known as SMILES strings, which show organic molecules and their structure as a sequence of letters and symbols. "We have now trained our chemical language model with pairs of strings," says Sanjana Srinivasan from Bajorath’s research group. "One of the strings described a molecule that we know only acts against one target protein. The other represented a compound that, in addition to this protein, also influences a second target protein."

The model was fed with more than 70,000 of these pairs. This allowed it to acquire an implicit knowledge of how the normal active compounds differed from those with the double effect. "When we then fed it with a compound against a target protein, it suggested molecules on this basis that would act not only against this protein but also against another," explains Bajorath.

The training compounds with the double effect often target proteins that are similar and thus perform a similar function in the body. In pharmaceutical research, however, people are also looking for active ingredients that influence completely different classes of enzymes or receptors. To prepare the AI for this task, fine-tuning took place after the general learning phase. The researchers used several dozen special training pairs to teach the algorithm which different classes of proteins the suggested compounds should target. This is a bit like instructing ChatGPT not to create a sonnet this time, but instead a limerick.

After the fine-tuning, the model actually spat out molecules that have already been shown to act against the desired combinations of target proteins. "This shows that the process works," says Bajorath. In his opinion, however, the strength of the approach is not that new compounds exceeding the effect of available pharmaceuticals can immediately be found. "It is more interesting, from my point of view, that the AI often suggests chemical structures that most chemists would not even think of right away," he explains. "To a certain extent, it triggers ‘out of the box’ ideas and comes up with original solutions that can lead to new design hypotheses and approaches."

Srinivasan, Sanjana et al.
Generation of dual-target compounds using a transformer chemical language model.
Cell Reports Physical Science, 2024. doi: 10.1016/j.xcrp.2024.102255

Most Popular Now

Commission Joins Forces with Venture Cap…

The Commission has launched a Trusted Investors Network bringing together a group of investors ready to co-invest in innovative deep-tech companies in Europe together with the EU. The Union's investment...

Philips and Medtronic Advocacy Partnersh…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Medtronic Neurovascular, a leading innovator in neurovascular therapies, today announced a strategic advocacy partnership. Delivering timely stroke...

Wearable Cameras Allow AI to Detect Medi…

A team of researchers says it has developed the first wearable camera system that, with the help of artificial intelligence (AI), detects potential errors in medication delivery. In a test whose...

New AI Tool Predicts Protein-Protein Int…

Scientists from Cleveland Clinic and Cornell University have designed a publicly-available software and web database to break down barriers to identifying key protein-protein interactions to treat with medication. The computational tool...

AI for Real-Rime, Patient-Focused Insigh…

A picture may be worth a thousand words, but still... they both have a lot of work to do to catch up to BiomedGPT. Covered recently in the prestigious journal Nature...

New Research Shows Promise and Limitatio…

Published in JAMA Network Open, a collaborative team of researchers from the University of Minnesota Medical School, Stanford University, Beth Israel Deaconess Medical Center and the University of Virginia studied...

G-Cloud 14 Makes it Easier for NHS to Bu…

NHS organisations will be able to save valuable time and resource in the procurement of technologies that can make a significant difference to patient experience, in the latest iteration of...

Start-Ups will Once Again Have a Starrin…

11 - 14 November 2024, Düsseldorf, Germany. The finalists in the 16th Healthcare Innovation World Cup and the 13th MEDICA START-UP COMPETITION have advanced from around 550 candidates based in 62...

Hampshire Emergency Departments Digitise…

Emergency departments in three hospitals across Hampshire Hospitals NHS Foundation Trust have deployed Alcidion's Miya Emergency, digitising paper processes, saving clinical teams time, automating tasks, and providing trust-wide visibility of...

MEDICA HEALTH IT FORUM: Success in Maste…

11 - 14 November 2024, Düsseldorf, Germany. How can innovations help to master the great challenges and demands with which healthcare is confronted across international borders? This central question will be...

A "Chemical ChatGPT" for New M…

Researchers from the University of Bonn have trained an AI process to predict potential active ingredients with special properties. Therefore, they derived a chemical language model - a kind of...

Siemens Healthineers co-leads EU Project…

Siemens Healthineers is joining forces with more than 20 industry and public partners, including seven leading stroke hospitals, to improve stroke management for patients all over Europe. With a total...